Cerus Signs Five-Year Agreement With Belgian Red Cross Flanders for the INTERCEPT Blood System for Platelets

  Cerus Signs Five-Year Agreement With Belgian Red Cross Flanders for the
  INTERCEPT Blood System for Platelets

Business Wire

CONCORD, Calif. -- May 29, 2014

Cerus Corporation (NASDAQ: CERS) announcedtoday that the Belgian Red Cross
Flanders (RC-F) has signed a five-year agreement to purchase the INTERCEPT
Blood System for platelets. RC-F is one of two major Red Cross blood services
in Belgium, and supplies approximately 37,000 platelet components to the
northern, or Flemish, region of Belgium.

“We believe that INTERCEPT was selected for implementation in Flanders based
on the product's accumulated hemovigilance and clinical data, which was
thoroughly reviewed by the Belgian Red Cross Flanders as part of the
technology’s validation,” said Caspar Hogeboom, president of Cerus Europe and
EEMEA. “We are extremely pleased and proud to supply INTERCEPT to all blood
centers across Belgium, contributing toward the country's goal of universal
pathogen inactivation for platelets and plasma.”

The Belgian Red Cross Flanders’ decision to proceed with the INTERCEPT Blood
System is a key step toward making pathogen inactivation the standard of care
in Europe. With approximately 65,000 platelet units produced annually, Belgium
joins countries such as Switzerland, Iceland and Kuwait in making pathogen
inactivated blood components generally available for all patients.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of
blood safety. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the world. In
the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood
System for plasma and platelets. The INTERCEPT red blood cell system is in
clinical development.

See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Contact:

Cerus Corporation
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations
 
Press spacebar to pause and continue. Press esc to stop.